Three Persistent Issues in Analysis of Clinical Trials Involving Diagnostic Contrast Agents Robert G. LehrFranciska K. Kashanian Clinical Trials 30 December 2009 Pages: 525 - 532
Compliance Analysis as Additional Evidence for Efficacy in Clinical Trials: Perspectives of the Swedish Medical Products Agency Karin HedenmalmGunnar Alvan Clinical Trials 30 December 2009 Pages: 533 - 538
Good Practices for Adaptive Clinical Trials in Pharmaceutical Product Development Brenda GaydosKeaven M. AndersonMichael Krams Biostatistics 30 December 2009 Pages: 539 - 556
Unconditional Exact Tests for Dichotomous Data in the Comparison of Two Treatments with One Control Group Seung-Ho Kong Biostatistics 30 December 2009 Pages: 557 - 565
A Study of the Classical Asymptotic Noninferiority Test for Two Binomial Proportions Félix Almendra-Arao Biostatistics 30 December 2009 Pages: 567 - 571
Qualified Statisticians in the European Pharma Industry: Present and Future Directions Zoë WilliamsKit RoesNigel Howitt Biostatistics 30 December 2009 Pages: 573 - 583
Weibull Failure-Time Mixture Models for Evaluating Efficacy in the Presence of a Biomarker Kallappa M. Koti Biostatistics 30 December 2009 Pages: 585 - 593
Repeated Measures Analyses in Clinical Trials with Titration Visits Phillip DinhPeiling Yang Biostatistics 30 December 2009 Pages: 595 - 602
Constant Vigilance: The Role of Pharmaceutical Companies in Medicine Safety Gretchen S. DieckSusan BetgerAlun Tanner Drug Safety and Risk Assessment 30 December 2009 Pages: 603 - 616
Perception of Risk through Phases of Drug Research and Development: Questionnaire Survey Ivor CowlrickRoland WolfMichael Olausson Drug Safety and Risk Assessment 30 December 2009 Pages: 617 - 622
Good Pharmacovigilance Practice: The Way Forward? Monika PietrekRosalind CoulsonAndrzej Czarnecki Drug Safety and Risk Assessment 30 December 2009 Pages: 623 - 632
Review of Targeted Regulatory Writing Techniques Steven F. Hoff Book Review 30 December 2009 Pages: 633 - 634
